INS and hypertensive disorder: Patients initiating exenatide b.i.d. had a statistically higher incidence of comorbidities than patients initiating insulin (P = 0.0014), i.e., a diagnosis of hypertension (69.5% vs. 65.3%, respectively) and hyperlipidemia (54.5% vs. 48.7%, respectively).